Table 1 Patient characteristics and (in the last column) answers to the question about inclusion in the randomized QUARTZ study (number of participants who would have felt comfortable enrolling the patient)
Patient nr. | Age in years | NSCLC type | Primary tumor controlled | Other metastases | KPS | Largest lesion size [cm] | Lesion number (MRI) | Time int. [mo]a | Mol DS-GPA | DS-GPA | OS predb | QUARTZ incl. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 69 | squamous cell | yes | hep | 50 | 3.8 | 3 | 10 | 1.0 | 0.5 | 2.3 | 2 |
2 | 60 | poorly diff. | no | lym, adr, hep, ski | 50 | 1.3 | 2 | 2 | 1.0 | 1.0 | 2.7 | 2 |
3 | 58 | adeno NSCLC | no | hep, oss, oth | 60 | 4.5 | 3 | 0 | 1.0 | 1.0 | 3.1 | 2 |
4 | 69 | poorly diff. | no | hep, oss | 60 | 2.1 | 1 | 8 | 1.0 | 1.0 | 2.6 | 2 |
5 | 61 | poorly diff. | no | hep, adr, pul | 60 | 3.3 | 7 | 10 | 0.5 | 0.0 | 2.6 | 2 |
6 | 64 | squamous cell | no | pul, kidney | 70 | 1.5 | 1 | 20 | 1.0 | 1.5 | 2,6 | 0 |
7 | 85 | squamous cell | no | pul | 60 | 1.8 | 1 | 18 | 0.5 | 1.0 | < 2.0 | 2 |
8 | 66 | adeno NSCLC | no | oss, adr, lym | 60 | 1.0 | 7 | 0 | 0.5 | 0.0 | 2.8 | 1 |
9 | 65 | poorly diff. | no | pul, oth | 50 | 2.0 | 2 | 5 | 1.0 | 0.5 | 2.4 | 2 |
10 | 77 | adeno NSCLC | yes | none | 50 | 2.3 | 6 | 12 | 1.0 | 1.0 | 3.8 | 1 |
11 | 62 | adeno NSCLC | yes | adr | 70 | 2.1 | 5 | 29 | 0.5 | 0.5 | 4.1 | 1 |
12 | 78 | adeno EGFR mut. | yes | oss | 60 | 4.0 | 4 | 54 | 1.5 | 0.0 | 2.6 | 0 |
13 | 64 | adeno NSCLC | yes | oss, adr, oth | 50 | 1.4 | 7 | 3 | 0.5 | 0.0 | 3.4 | 2 |
14 | 68 | adeno NSCLC | no | pul, pleura | 60 | 2.2 | 3 | 8 | 1.0 | 0.5 | 2.6 | 1 |
15 | 66 | squamous cell | yes | hep, adr, oss | 70 | 1.5 | 18 | 8 | 0.5 | 0.5 | 3.0 | 3 |
16 | 65 | adeno NSCLC | yes | pul | 70 | 3.3 | 4 | 22 | 1.0 | 0.5 | 4.2 | 0 |
17 | 53 | adeno NSCLC | no | hep, adr, oss | 70 | 3.4 | 7 | 2 | 0.5 | 1.0 | 3.8 | 1 |